Abstract 1836P
Background
PRESIDE (NCT02288247) was a randomised, international trial that met its primary endpoint of prolonged progression-free survival (PFS) with continued ENZ beyond progression in patients (pt) starting Doc. A pre-specified aim of PRESIDE was to test for androgen receptor (AR) blood-based biomarkers to test for differential benefit.
Methods
Pt who participated in PRESIDE, consented to the biomarker sub-study and donated blood at randomization (Period 2 baseline, P2BL) were included. Blood was also collected on treatment (P2 Week [W] 4 and 13), progression and follow up. Pre-specified primary objectives were to evaluate PFS for 1) ENZ versus (v) Placebo (P) in pt split by +/- plasma AR gain or AR-V7 in circulating tumor cells (CTC) at P2BL and 2) PFS for all pt split by +/- tumor in plasma DNA (ptDNA) at P2W4. Custom targeted next-generation sequencing on plasma DNA was performed using a bespoke panel (PCF SELECT). Identification of CTC +/- AR-V7 in whole blood samples was performed by Epic Sciences (San Diego, California).
Results
Of 271 pt randomised to ENZ / P, 157 (57.9%, 79 on ENZ + Doc, 78 on P + Doc) donated blood. 100 (64%) were plasma AR wild type (wt), 56 (36%) had AR gain. 126 (80%) were AR-V7 negative (-), 17 (11%) AR-V7 positive (+). AR status not available for plasma DNA (1 pt) and CTC (14 pt, 9%). Pt who were AR wt and AR-V7- (N=87, 55%) had significantly prolonged PFS from continuing ENZ (11.2 months (m) v 8.7 m P, HR: 0.49; 95% CI: 0.29-0.82, p=0.006), whilst pt with AR gain or AR-V7+ (N=62) did not (6.2 m ENZ v 7.9 m P; HR: 1.29; p=0.44). Restricted mean survival times at 18 m for AR wt and AR-V7- was 11.5 m ENZ v 8.9 m P, p=0.0046, for AR gain or AR-V7 + was 7.9 m ENZ vs 7.1 m P, p=0.5023. Compared with negative ptDNA at P2W4 (99, 74% of 134 pt included), pt with positive ptDNA (35, 26%) had significantly shorter PFS (5.4 m vs 10.8 m, HR: 1.92; 95% CI: 1.14-3.23, p=0.0145).
Conclusions
The benefit of continuing ENZ beyond progression with Doc vs Doc alone is greatest in patient with no evidence of plasma AR gain or AR-V7+ CTC. Plasma tumor DNA detection after 3 weeks Doc +/- ENZ identifies patients with shorter PFS.
Clinical trial identification
NCT02288247.
Editorial acknowledgement
Legal entity responsible for the study
Prof. Gerhardt Attard (Principal Investigator), Head of Treatment Resistance Group, University College London.
Funding
Academic group (UCL) with funding from Astellas, CRUK (Cancer Research United Kingdom) and SEOM (Spanish Society of Medical Oncology).
Disclosure
M. Ruiz Vico: Financial Interests, Institutional, Research Grant: Astellas Pharma Europe Ltd; Financial Interests, Personal, Research Grant, 2-year FSEOM grant for training in translational research in reference centres abroad. Spanish Society of Medical Oncology (SEOM). Awarded in 2018: Spanish Soctiey of Medical Oncology (SEOM); Non-Financial Interests, Project Lead: Astellas Pharma Europe Ltd. D.E. Castellano Gauna: Financial Interests, Personal, Advisory Board: Pfizer, Roche, BMS, Janssen, Astellas, MSD, Ipsen, AstraZeneca Novartis, GSK; Financial Interests, Institutional, Local PI: Pfizer, Roche, MSD, BMS, AstraZeneca Janssen, Astellas, Ipsen, Exelisis, Eisai, Lilly, Bayer, GSK, Clovis, QED Therapeutics; Non-Financial Interests, Personal, Other, Executive member: SOGUG (Spanish Oncology Genito-Urinary Group) Foundation. K.D. Martins, G. Gourgioti, A. Serikoff: Financial Interests, Personal, Full or part-time Employment: Astellas Europe Pharma Ltd.. K. Iwata: Financial Interests, Personal, Full or part-time Employment: Astellas Pharma USA. L. Astrom: Financial Interests, Personal, Financially compensated role: Merck Sharpe & Dohme, Pfizer, Merck, Janssen; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: Merck Sharpe & Dohme. V. Matveev: Financial Interests, Personal, Financially compensated role: Astellas Pharma. S. Feyerabend: Financial Interests, Personal, Advisory Board: Janssen, Astellas, Bayer, Aventis; Financial Interests, Personal, Financially compensated role: Janssen; Financial Interests, Personal, Other, Travel expenses and accommodation: Aventis. E. Senkus-Konefka: Financial Interests, Personal, Advisory Board: AstraZeneca, Eli Lilly, Novartis; Financial Interests, Personal, Invited Speaker: AstraZeneca, Cancérodigest, Eli Lilly, Gilead, high5md, Novartis, Pfizer, MSD; Financial Interests, Personal, Writing Engagement: AstraZeneca; Financial Interests, Personal, Other, commenting on scientific meeting in social media: Curio Science; Financial Interests, Personal, Other, travel expenses: Gilead, Egis, Novartis, Roche; Financial Interests, Personal, Stocks/Shares: AstraZeneca, Eli Lilly, Pfizer; Financial Interests, Personal, Royalties: Springer; Financial Interests, Personal and Institutional, Local PI: Amgen, Eli Lilly, Novartis, OBI Pharma, Samsung; Financial Interests, Personal and Institutional, Other, SI: AstraZeneca, Roche, Pfizer. S. Gupta: Financial Interests, Personal, Full or part-time Employment, Employee: Epic Sciences. A.S. Merseburger: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Astellas, Bayer, BMS, Eisai, Ferring, Ipsen, MSD, Merck Serono, Janssen, Takeda, TEVA, Novartis, Pfizer, Recordati, Roche, EUSAPharm; Financial Interests, Personal and Institutional, Research Funding: AstraZeneca, Astellas, Bayer, BMS, Ipsen, Janssen, EUSAPharm, MSD, Merck Serono, Novartis, Pfizer, Takeda, TEVA, Roche. G. Attard: Financial Interests, Personal, Invited Speaker: Janssen, Astellas, AstraZeneca; Financial Interests, Personal, Advisory Board: Janssen, Astellas, Novartis, Bayer, AstraZeneca, Pfizer, Sanofi, Sapience, Orion, Novartis; Financial Interests, Personal, Royalties, Included in list of rewards to discoverers of abiraterone: Institute of Cancer Research; Financial Interests, Institutional, Advisory Board: Artera, Veracyte; Financial Interests, Institutional, Research Grant: Janssen, Astellas, Novartis; Financial Interests, Institutional, Coordinating PI: Janssen; Financial Interests, Institutional, Local PI: Novartis, Pfizer; Non-Financial Interests, Principal Investigator: Janssen, Astellas; Non-Financial Interests, Advisory Role: Janssen, AstraZeneca; Non-Financial Interests, Project Lead: Artera, Veracyte. All other authors have declared no conflicts of interest.
Resources from the same session
1982P - Transcriptomic analysis and tumor microenvironment (TME) classification reveals unique immune biology in HIV patients with Kaposi sarcoma (KS)
Presenter: Jihua Yang
Session: Poster session 15
1983P - Palliative spatially fractionated stereotactic radiation therapy (Lattice) for large sarcoma
Presenter: Gabriela Studer
Session: Poster session 15
1984P - Sex differences in anticancer treatment delivery and toxicity in patients with sarcoma in a reference center
Presenter: Ilaria Tortorelli
Session: Poster session 15
1985P - Expert sarcoma care is the need of the hour: Diagnostic and management challenges at a tertiary-care centre in India
Presenter: Ghazal Tansir
Session: Poster session 15
1986P - Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: An analysis from the OnCovid registry
Presenter: Alessandro Mazzocca
Session: Poster session 15
1987TiP - Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas: EFTISARC-NEO trial
Presenter: Katarzyna Kozak
Session: Poster session 15
2213P - Impact of the diagnosis-to-treatment interval on the survival of patients with papillary thyroid cancer
Presenter: Tingting Wei
Session: Poster session 15
2214P - Identification of prognosis-associated genes in locally advanced well-differentiated thyroid cancer using TCGA cohort analysis
Presenter: Ah Ra Jung
Session: Poster session 15
2216P - Clinicopathologic and genetic characteristics of patients of different ages with diffuse sclerosing variant papillary thyroid carcinoma
Presenter: Soo Young Kim
Session: Poster session 15
2220P - MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Presenter: Neus Baste Rotllan
Session: Poster session 15